Icaritin

Drug Profile

Icaritin

Alternative Names: SNG 162

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator Shenogen Pharma
  • Developer Chinese Academy of Medical Sciences; Shenogen Pharma
  • Class Antineoplastics; Benzopyrans; Flavonoids; Phenyl ethers; Small molecules
  • Mechanism of Action Estrogen receptor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatocellular carcinoma
  • No development reported Breast cancer; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Breast-cancer(Late-stage disease, Second-line therapy or greater) in China (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top